Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
Phase 1
132
about 2.9 years
18+
8 sites in CA, FL, MI +4
What this study is about
This trial is testing a new drug called MOMA-341, which is given by mouth, to see if it's safe and effective for people with advanced solid tumors. The goal is to determine the best dose of MOMA-341.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Immunotherapy
- 2.Take Irinotecan
- 3.Take MOMA-341
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
immunotherapy, irinotecan
Primary: Number of participants with AEs, dose-limiting toxicities (DLTs), serious AEs (SAEs), and/or AEs leading to discontinuation
Secondary: Disease control rate (DCR), Duration of response (DOR), Objective response rate (ORR), Overall survival (OS), PK parameter; area under curve (AUC) of MOMA-341, PK parameter; half-life (T1/2) of MOMA-341, PK parameter; maximum concentration (Cmax) of MOMA-341, PK parameter; plasma exposure of irinotecan
Oncology